SCHEMBL5036760

SCHEMBL5036760

Cc1ccc(CNc2nc(N)nc(-c3ccco3)c2C#N)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.49
ADORA1 P30542 6/20 0.49
ADORA2B P29275 3/20 0.49
TLR7 Q9NYK1 1/20 0.43
ALDH1A1 P00352 10/20 0.42
KDM4E B2RXH2 9/20 0.42
HPGD P15428 8/20 0.42
POLB P06746 3/20 0.42
LMNA P02545 1/20 0.42
SMARCA2 P51531 1/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 1/20 0.42
HIF1A Q16665 1/20 0.42
GAA P10253 5/20 0.41
HSD17B10 Q99714 4/20 0.41
TDP1 Q9NUW8 2/20 0.40
TSHR P16473 1/20 0.40
PDE10A Q9Y233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041593 0.86 ADORA2A (0.49) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL5037033 0.85 KDM4E (0.53) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6441566 0.85 ADORA2A (0.47) ADORA2AADORA1ADORA2BTLR7ALDH1A1
SCHEMBL5039700 0.85 ADORA2A (0.53) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6441233 0.85 ADORA2A (0.55) ADORA2AADORA1ADORA2BTLR7ALDH1A1
SCHEMBL5132209 0.84 ADORA2A (0.47) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6443508 0.83 TLR7 (0.41) ADORA2AADORA1ADORA2BTLR7MEN1
SCHEMBL5040165 0.83 ALDH1A1 (0.41) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6441924 0.83 TLR7 (0.40) ADORA2AADORA1ADORA2BTLR7ALDH1A1
SCHEMBL6446015 0.81 ADORA2A (0.61) ADORA2AADORA1ADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4064671-B2 2008-03-19 JP claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP claimed
JP-2003523380-A 2003-08-05 JP claimed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US claimed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP claimed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US claimed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO claimed
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.